Table 1.

Intensity of CD25 and CD69 expression assessed as mean fluorescence channel (MFC) among activated T lymphocytes

% CD3+CD25+ cells remaining
CD25 MFC among remaining activated T cells
CD69 MFC among remaining activated T cells
PHA-stimulated samples    
    0 nM bortezomib   90   971   207  
    10 nM bortezomib   82   929   230  
    100 nM bortezomib   73*  771*  200  
    1000 nM bortezomib   69*  642*  174* 
αCD3/αCD28-stimulated samples    
    0 nM bortezomib   64   555   276  
    10 nM bortezomib   56   433   256  
    100 nM bortezomib   34*  208*  201  
    1000 nM bortezomib
 		 5*
 		 85*
 		 166*
 
% CD3+CD25+ cells remaining
CD25 MFC among remaining activated T cells
CD69 MFC among remaining activated T cells
PHA-stimulated samples    
    0 nM bortezomib   90   971   207  
    10 nM bortezomib   82   929   230  
    100 nM bortezomib   73*  771*  200  
    1000 nM bortezomib   69*  642*  174* 
αCD3/αCD28-stimulated samples    
    0 nM bortezomib   64   555   276  
    10 nM bortezomib   56   433   256  
    100 nM bortezomib   34*  208*  201  
    1000 nM bortezomib
 		 5*
 		 85*
 		 166*
 
*

P < .05 compared with the respective value of the samples without bortezomib.

View Large